A Rice University student decided to use his data science skills for good. Photo courtesy of Biokind Analytics

For Alex Han, it all started with peanut butter.

Han was a high school student in Korea when he learned that the spread is a pure odorant that could be used to test smell in each hemisphere of the brain—issues on the left side was thought to be a predictor for Alzheimer’s disease. He later learned that the method wasn’t as airtight as previously thought, but Han was hooked. Alzheimer’s research became the teenager’s passion. While still in high school, Han began volunteering for Alzheimer’s Los Angeles, translating their brochures into Korean.

When it came time to choose a college, Han says Rice University appealed to him for many reasons.

“I loved the atmosphere. I loved the campus—it’s so beautiful. The diverse food, the people, I even liked the highway,” he says of Houston. “In Korea, everything is so close and compact. I loved the whole scenario of the city.”

A scholarship was also part of the appeal, as well as the pull of the world’s largest medical center. Han’s instincts were correct. Now, a junior at Rice, he has been working at renowned geneticist Huda Zoghbi’s Baylor College of Medicine lab for almost two years.

But dividing his obligations between full-time studies and his wet lab position wasn’t enough to keep Han’s active mind occupied. Last May, the statistics and biochemistry student began another endeavor that uses both his specialties. It was then that he founded Biokind Analytics. The nonprofit was designed to explore how data science can support health care nonprofits.

Han reached out to Alzheimer’s Los Angeles to offer his data analysis services on a volunteer basis and was shocked that the association had never considered it before.

“I was really surprised—even small stores and restaurants use statistics to boost their profits. [Alzheimer’s Los Angeles] receive a couple million dollars every year in donations. They have data stores but hadn’t really capitalized yet in the area of analytics.”

Han, along with a small team of Rice students, including vice president Zac Andrews and development director Masha Zaitsev, made Alzheimer’s Los Angeles a pet project, analyzing geospatial trends in its donorship and interpreting the past year’s donation trends. “We wanted to see if the demand was the same in Houston. We found that this pattern was consistent. A lot of nonprofits are willing to have us analyze the data sets they’ve already been tracking and provide data analysis for healthcare nonprofits.”

Less than a year after Han established Biokind Analytics, the 501(c)(3) already has seven chapters on college campuses around the country. From UC Davis and San Diego in the West to Brown University and the University of Virginia on the East Coast, the data science students have helped a diverse range of medical nonprofits, mostly based in the Houston area. They run the gamut from ALS Association of Texas to Nora’s Home, which serves organ failure and transplant patients.

Biokind Analytics has now completed seven projects and analyzed $100 million in funds. Each student group includes four to six members, mostly majors in the worlds of statistics, data science, and biochemistry, all working with the help of faculty advisors. At a total of about 35 students nationwide, Han says that he’s dedicated to growing at a steady pace to avoid potentially expanding too fast, too soon.

Another question for the future is what will happen to Biokind Analytics when Han completes his undergraduate studies in 2024. He plans to continue his medical studies with the goal of one day becoming a physician specializing in Alzheimer’s who uses data analytics to aid in patient care. But no matter how active Han continues to be in the nonprofit he started, his stated attachment to the cause and a growing group of both student leaders and healthcare associations eager for their services are sure to keep Biokind Analytics active long after graduation.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.